Full Press Release Details
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent No. 20260325541-A1, titled “Benzgalantamine for Treating Persistent Post-Concussion Symptoms.”The published application includes pending claims directe